Coherus Oncology Inc (CHRS) (Q3 2026) Earnings Call Highlights: Cost Cuts, Loqtorzi Growth and ...
Coherus Oncology Inc (CHRS) trimmed headcount by 30% and lowered its breakeven threshold while revising 2026 Loqtorzi guidance to $54-$57 million amid a sub-12-month cash runway. Related Stocks: CHRS ,